148 related articles for article (PubMed ID: 32277617)
1. Efficacy of bevacizumab combined with nedaplatin in the treatment of ovarian cancer and its effects on tumor markers and immunity of patients.
Zhang H; Chen C; Wang S; Li X; Fan T
J BUON; 2020; 25(1):80-86. PubMed ID: 32277617
[TBL] [Abstract][Full Text] [Related]
2. Observation of efficacy of TACE combined with HIFU on patients with middle-advanced liver cancer.
Zhang Q; Bian SQ; Lv W; Kou D; Hu HL; Guo SS; Cao ZS
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(3 Suppl):239-246. PubMed ID: 31389607
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Bevacizumab Combined with Albumin-Bound Paclitaxel in the Treatment of Platinum-Resistant Recurrent Ovarian Cancer.
Liu B; An R; Yu J
J BUON; 2019; 24(6):2303-2309. PubMed ID: 31983098
[TBL] [Abstract][Full Text] [Related]
4. Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors.
Chen F; Shen J; Wang J; Cai P; Huang Y
Cancer Manag Res; 2018; 10():1313-1318. PubMed ID: 29861641
[TBL] [Abstract][Full Text] [Related]
5. Effects of carboplatin combined with paclitaxel-based intraperitoneal hyperthermic perfusion chemotherapy on serum levels of HE4 and DJ-1 in patients with advanced recurrent ovarian cancer.
Su X; Sun X; Kang Y; Dai Y
Pak J Med Sci; 2022; 38(4Part-II):872-877. PubMed ID: 35634603
[TBL] [Abstract][Full Text] [Related]
6. Tumor markers in serum and ascites in the diagnosis of benign and malignant ascites.
Zhu FL; Ling AS; Wei Q; Ma J; Lu G
Asian Pac J Cancer Prev; 2015; 16(2):719-22. PubMed ID: 25684514
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9 in gastroenteropancreatic neuroendocrine neoplasms].
Chen L; Zhang Y; Chen M; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1002-1008. PubMed ID: 28900990
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effect of bevacizumab combined with paclitaxel and carboplatin on recurrent ovarian cancer.
Cong J; Liu R; Hou J; Wang X; Jiang H; Wang J
J BUON; 2019; 24(3):1003-1008. PubMed ID: 31424654
[TBL] [Abstract][Full Text] [Related]
9. Prognostic values of normal preoperative serum cancer markers for gastric cancer.
Feng F; Sun L; Liu Z; Liu S; Zheng G; Xu G; Guo M; Lian X; Fan D; Zhang H
Oncotarget; 2016 Sep; 7(36):58459-58469. PubMed ID: 27533455
[TBL] [Abstract][Full Text] [Related]
10. Research on application value of combined detection of serum CA125, HE4 and TK1 in the diagnosis of ovarian cancer.
Xi QP; Pu DH; Lu WN
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4536-4541. PubMed ID: 29131263
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of irinotecan combined with nedaplatin in the treatment of small cell lung cancer.
Fu J; Fang S; Wen Y; Wang Y; Yin X; Wang D
J BUON; 2020; 25(4):1707-1713. PubMed ID: 33099904
[TBL] [Abstract][Full Text] [Related]
12. Retrospective efficacy analysis of olaparib combined with bevacizumab in the treatment of advanced colorectal cancer.
Jiang YL; Fu XY; Yin ZH
World J Gastrointest Surg; 2023 May; 15(5):906-916. PubMed ID: 37342840
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of low-temperature plasma ablation combined with low-dose cisplatin chemotherapy in laryngeal carcinoma patients and its influence on tumor markers.
Wang P; Wang G
J BUON; 2021; 26(1):132-137. PubMed ID: 33721443
[TBL] [Abstract][Full Text] [Related]
14. Expression and clinical significance of tumor markers in ovarian mature cystic teratoma.
Chen JM; Gao HY; Wang Q; Li Q
Clin Exp Obstet Gynecol; 2016; 43(3):397-400. PubMed ID: 27328499
[TBL] [Abstract][Full Text] [Related]
15. Comparisons of efficacy and safety between docetaxel + cisplatin and paclitaxel + cisplatin and their effects on serum HE4, CA125 and ROMA indicators in patients with ovarian carcinoma.
Han L; Kuang L
J BUON; 2019; 24(4):1544-1548. PubMed ID: 31646806
[TBL] [Abstract][Full Text] [Related]
16. Comparisons of the survival time of patients with ovarian cancer adopting post-operative chemotherapy by use of paclitaxel combined with carboplatin or nedaplatin.
Gao H; Yuan L; Han Y
World J Surg Oncol; 2016 Jun; 14(1):168. PubMed ID: 27341795
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the importance of the serum levels of CA-125, CA15-3, CA-19-9, carcinoembryonic antigen and alpha fetoprotein for distinguishing benign and malignant adnexal masses and contribution of different test combinations to diagnostic accuracy.
Bozkurt M; Yumru AE; Aral I
Eur J Gynaecol Oncol; 2013; 34(6):540-4. PubMed ID: 24601047
[TBL] [Abstract][Full Text] [Related]
18. CA125 and HE4: Measurement Tools for Ovarian Cancer.
Zhao T; Hu W
Gynecol Obstet Invest; 2016; 81(5):430-5. PubMed ID: 27160726
[TBL] [Abstract][Full Text] [Related]
19. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin.
Stiekema A; Boldingh QJ; Korse CM; van der Noort V; Boot H; van Driel WJ; Kenter GG; Lok CA
Gynecol Oncol; 2015 Mar; 136(3):562-6. PubMed ID: 25560808
[TBL] [Abstract][Full Text] [Related]
20. Application of Joint Detection of AFP, CA19-9, CA125 and CEA in Identification and Diagnosis of Cholangiocarcinoma.
Li Y; Li DJ; Chen J; Liu W; Li JW; Jiang P; Zhao X; Guo F; Li XW; Wang SG
Asian Pac J Cancer Prev; 2015; 16(8):3451-5. PubMed ID: 25921161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
